C.J. Bol

681 citations
10 papers · 557 indexed · h-index 8

C.J. Bol

9 papers receiving 539 citations

Peers

C.J. Bol
Comparison fields: 5 of 57
  • Oncology 391
  • Hematology 61
  • Genetics 46
  • Pharmacology 35
  • Molecular Biology 271
Replace Greta Cipriani with:
Greta Cipriani Italy
Hiromi Tanii Japan
Seiji Doi Japan
Maria A.J. van Eijndhoven Netherlands
Olga Ujhelly Hungary
Joanna Regis United States
Ronald Drengler United States
Jean-Pierre Bizzari France
L‐M Ching New Zealand
Timothy M. Lestingi United States
C.J. Bol relative to Greta Cipriani Italy Greta Cipriani's profile →
Citations per field
00.5×1.6×
Greta Cipriani · 1×
Citations per year

Countries citing papers authored by C.J. Bol

Since Specialization
Citations

This map shows the geographic impact of C.J. Bol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.J. Bol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.J. Bol more than expected).

Fields of papers citing papers by C.J. Bol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.J. Bol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.J. Bol. The network helps show where C.J. Bol may publish in the future.

Co-authorship network

The 25 scholars most cited alongside C.J. Bol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C.J. Bol Line = papers co-authored together C.J. Bol links everyone, so they are left out of the graph.

All Works

10 of 10 papers shown
#Work
1 200910
2 200816
3 20028
4 200255
5 2002110
6 200155
7
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
200084
8 2000218
9 19991
10 19870

About C.J. Bol

C.J. Bol is a scholar working on Pharmacology, Oncology, Pediatrics, Perinatology and Child Health, Cardiology and Cardiovascular Medicine and Neurology, having authored 10 papers that have together received 557 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Treatment and Pharmacology (3 papers), Cardiac Valve Diseases and Treatments (2 papers), Pharmacological Effects and Toxicity Studies (2 papers), Coronary Interventions and Diagnostics (2 papers), Cancer-related Molecular Pathways (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (391 citations), Hematology (61 citations), Genetics (46 citations), Pharmacology (35 citations) and Molecular Biology (271 citations). C.J. Bol has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Peter Palmer, R. Woestenborghs, Ate van der Gaast, Lia van Zuylen, Alex Sparreboom, Jaap Verweij, C. Chow, R. B. Nussenblatt, Charles L. Bowden and Vladimir Piotrovsky. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Journal of Interventional Cardiology, American Heart Journal and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026